ArticleThe New England journal of medicine2017
Influenza Vaccine Effectiveness in the United States during the 2015-2016 Season.
Registry-linked trialOpen access · bronzeAbstract read
In one paragraph
Article in The New England journal of medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04584645 (Increasing Influenza Vaccination in Individuals With Cardiovascular Conditions), which is not on this map. Cited by 170 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 4 pooled it
27.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Increasing Influenza Vaccination in Individuals With Cardiovascular Conditions: Assessing the Effectiveness of a Digital Intervention in a Decentralized Randomized Controlled Trial
Who cites it
170 citing papers in PubMed, 4 syntheses or guidelines pooled it, 297 citations in OpenAlex.
- Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis.The Lancet. Respiratory medicine · 2023Pooled it
- The Use of Test-negative Controls to Monitor Vaccine Effectiveness: A Systematic Review of Methodology.Epidemiology (Cambridge, Mass.) · 2020Pooled it
- Update: ACIP Recommendations for the Use of Quadrivalent Live Attenuated Influenza Vaccine (LAIV4) - United States, 2018-19 Influenza Season.MMWR. Morbidity and mortality weekly report · 2018Guideline
- Influenza vaccines in immunosuppressed adults with cancer.The Cochrane database of systematic reviews · 2018Pooled it
- Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccination Against Hospitalizations and Deaths According to Frailty Score: A Post Hoc Analysis of the DANFLU-1 Randomized Trial.The Journal of infectious diseases · 2026Trial
- Programmatic Effectiveness of a Pediatric Typhoid Conjugate Vaccine Campaign in Navi Mumbai, India.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- An evaluation of a test-negative design for EV-71 vaccine from a randomized controlled trial.Human vaccines & immunotherapeutics · 2021Trial
- Impaired memory B-cell recall responses in the elderly following recurrent influenza vaccination.PloS one · 2021Trial
- Immunogenicity and Viral Shedding of Russian-Backbone, Seasonal, Trivalent, Live, Attenuated Influenza Vaccine in a Phase II, Randomized, Placebo-Controlled Trial Among Preschool-Aged Children in Urban Bangladesh.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- The Effect of Preexisting Immunity on Virus Detection and Immune Responses in a Phase II, Randomized Trial of a Russian-Backbone, Live, Attenuated Influenza Vaccine in Bangladeshi Children.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Absolute and Relative Effectiveness of Cell Culture-Based and Egg-Based Quadrivalent Inactivated Influenza (Flu) Vaccine Products From the 2014-2015 to 2018-2019 Seasons, US Flu VE Network.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Observational
- Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- A study on knowledge, attitude and practices (KAP) towards adult immunizations among health care professionals.Journal of family medicine and primary care · 2026Article
- Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China.Human vaccines & immunotherapeutics · 2025Article
- Influenza vaccine strain selection with an AI-based evolutionary and antigenicity model.Nature medicine · 2025Article
- Photoinactivation of influenza viruses by modulated indoor daylight spectrum and intensity.Applied and environmental microbiology · 2025Article
- Optimized high-throughput whole-genome sequencing workflow for surveillance of influenza A virus.Genome medicine · 2025Article
- Effectiveness of Cell Culture-Based Influenza Vaccine, 2023-2024.Journal of the Pediatric Infectious Diseases Society · 2025Article
- Impact of unequal testing on vaccine effectiveness estimates across two study designs: a simulation study.Nature communications · 2025Article
- Retrospective Epidemiological Analysis of Influenza A Infections in a Single Hospital in Korea (2007-2024): Age, Sex, and Seasonal Patterns.Pathogens (Basel, Switzerland) · 2025Article
110 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
15 authors at 5 institutions in 1 country.
Michael L JacksonFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Jessie R ChungFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Lisa A JacksonFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
C Hallie PhillipsFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Joyce BenoitFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Arnold S MontoFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Emily T MartinFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Edward A BelongiaFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Huong Q McLeanFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Manjusha GaglaniFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Kempapura MurthyFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Richard ZimmermanFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Mary P NowalkFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Alicia M FryFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Brendan FlanneryFrom the Group Health Research Institute (now Kaiser Permanente Washington Health Research Institute), Seattle (M.L.J., L.A.J., C.H.P., J.B.); Centers for Disease Control and Prevention, Atlanta (J.R.C., A.M.F., B.F.); University of Michigan, Ann Arbor (A.S.M., E.T.M.); Marshfield Clinic Research Foundation, Marshfield WI (E.A.B., H.Q.M.); Baylor Scott and White Health, Texas A&M College of Medicine, Temple (M.G., K.M.); and University of Pittsburgh, Pittsburgh (R.Z., M.P.N.).
Seattle University · USBaylor Scott & White Health · USMarshfield Clinic · USUniversity of Michigan–Ann Arbor · USUniversity of Pittsburgh · US
Funding
University of Pittsburgh Clinical and Translational Science InstituteUL1TR001857 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2016 to 2025
$129.3MUNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9MUniversity of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8MUS Influenza Vaccine Effectiveness NetworkU01IP001034 · IP · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MONTO, ARNOLD S · 2016 to 2020
$10.0MAnnual Estimates of Influenza Vaccine Effectiveness and Evaluation of Immune Response in a Wisconsin PopulationU01IP001038 · IP · MARSHFIELD CLINIC RESEARCH FOUNDATION · PI BELONGIA, EDWARD · 2016 to 2020
$8.0MProspective annual estimates of influenza vaccine effectiveness and burden of diseaseU01IP001037 · IP · KAISER FOUNDATION RESEARCH INSTITUTE · PI JACKSON, MICHAEL L · 2016 to 2020
$7.8MCore_plus_Option_A_B_Proposal for Influenza Vaccine Effectiveness ResearchU01IP000474 · IP · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MONTO, ARNOLD S · 2011 to 2015
$6.2MCore_plus Option_A_C_Influenza Surveillance and Vaccine Effectiveness in a LargeU01IP000467 · IP · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ZIMMERMAN, RICHARD K · 2011 to 2015
$5.9MCore_plus Option_B_C_Influenza Vaccine Effectiveness in a Wisconsin PopulationU01IP000471 · IP · MARSHFIELD CLINIC RESEARCH FOUNDATION · PI BELONGIA, EDWARD · 2011 to 2015
$5.6MCore_Prospective population-based estimation of influenza vaccine effectiveness aU01IP000466 · IP · KAISER FOUNDATION HEALTH PLAN OF WASHINGTON · PI JACKSON, MICHAEL L · 2011 to 2015
$4.1MCore_RT-PCR based Case-Control: Apt Measure of Influenza Vaccine EffectivenessU01IP000473 · IP · SCOTT AND WHITE MEMORIAL HOSPITAL · PI GAGLANI, MANJUSHA · 2011 to 2015
$4.0MACL HHS U01IP000473NCATS NIH HHS UL1 TR000005NCATS NIH HHS UL1 TR001857NCIRD CDC HHS U01 IP000466NCIRD CDC HHS U01 IP000467NCIRD CDC HHS U01 IP000471NCIRD CDC HHS U01 IP000473NCIRD CDC HHS U01 IP000474NCIRD CDC HHS U01 IP001034NCIRD CDC HHS U01 IP001037NCIRD CDC HHS U01 IP001038NCRR NIH HHS UL1 RR024153
Abstract
backgroundThe A(H1N1)pdm09 virus strain used in the live attenuated influenza vaccine was changed for the 2015-2016 influenza season because of its lack of effectiveness in young children in 2013-2014. The Influenza Vaccine Effectiveness Network evaluated the effect of this change as part of its estimates of influenza vaccine effectiveness in 2015-2016.
methodsWe enrolled patients 6 months of age or older who presented with acute respiratory illness at ambulatory care clinics in geographically diverse U.S. sites. Using a test-negative design, we estimated vaccine effectiveness as (1-OR)×100, in which OR is the odds ratio for testing positive for influenza virus among vaccinated versus unvaccinated participants. Separate estimates were calculated for the inactivated vaccines and the live attenuated vaccine.
resultsAmong 6879 eligible participants, 1309 (19%) tested positive for influenza virus, predominantly for A(H1N1)pdm09 (11%) and influenza B (7%). The effectiveness of the influenza vaccine against any influenza illness was 48% (95% confidence interval [CI], 41 to 55; P<0.001). Among children 2 to 17 years of age, the inactivated influenza vaccine was 60% effective (95% CI, 47 to 70; P<0.001), and the live attenuated vaccine was not observed to be effective (vaccine effectiveness, 5%; 95% CI, -47 to 39; P=0.80). Vaccine effectiveness against A(H1N1)pdm09 among children was 63% (95% CI, 45 to 75; P<0.001) for the inactivated vaccine, as compared with -19% (95% CI, -113 to 33; P=0.55) for the live attenuated vaccine.
conclusionsInfluenza vaccines reduced the risk of influenza illness in 2015-2016. However, the live attenuated vaccine was found to be ineffective among children in a year with substantial inactivated vaccine effectiveness. Because the 2016-2017 A(H1N1)pdm09 strain used in the live attenuated vaccine was unchanged from 2015-2016, the Advisory Committee on Immunization Practices made an interim recommendation not to use the live attenuated influenza vaccine for the 2016-2017 influenza season. (Funded by the Centers for Disease Control and Prevention and the National Institutes of Health.).
Indexed as
AdolescentAdultAgedAge FactorsChildChild, PreschoolFemaleHumansInfantInfluenza A Virus, H1N1 SubtypeInfluenza B virusInfluenza, HumanInfluenza VaccinesMaleMiddle AgedTreatment OutcomeInfluenza VaccinesVaccines, AttenuatedVaccines, Inactivated
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT04584645ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.